The growth in the price of cancer medicines in the U.S. averaged 3.6 percent last year, a drop from 4.7 percent in 2015, after accounting for rebates and discounts that drug makers paid to health insurers, according to a new report.
Meanwhile, the plethora of new cancer drugs is projected to generate increased spending of 6 percent to 9 percent annually through 2021, when global costs are forecast to exceed $147 billion, which is in keeping with the nearly 9 percent compounded annual spending growth rate that was seen over the past five years, according to the market research arm of QuintilesIMS.
About the Author Reprints
